Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides.

Détails

Demande d'une copieDemande d'une copie
ID Serval
serval:BIB_6FD3B35B8A79
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Lettre (letter): communication adressée à l'éditeur.
Collection
Publications
Institution
UNIL/CHUV
Titre
Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides.
Périodique
Journal of Allergy and Clinical Immunology
Auteur⸱e⸱s
Spertini F., Perrin Y., Audran R., Pellaton C., Boudousquié C., Barbier N., Thierry A.C., Charlon V., Reymond C.
ISSN
0091-6749, 1097-6825 (Electronic)
Statut éditorial
Publié
Date de publication
2014
Volume
134
Numéro
1
Pages
239-240.e13
Langue
anglais
Notes
Publication types: Clinical Trial, Phase I ; Clinical Trial, Phase II ; Letter ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Mots-clé
Adult, Antigens, Plant/chemistry, Antigens, Plant/immunology, Asthma/immunology, Asthma/therapy, Conjunctivitis, Allergic/immunology, Conjunctivitis, Allergic/therapy, Desensitization, Immunologic/methods, Female, Humans, Immunization Schedule, Immunoglobulin E/blood, Immunoglobulin G/blood, Immunologic Memory, Injections, Subcutaneous, Middle Aged, Peptides/administration & dosage, Peptides/adverse effects, Rhinitis, Allergic/immunology, Rhinitis, Allergic/therapy
OAI-PMH
oai:serval.unil.ch:BIB_6FD3B35B8A79
DOI
10.1016/j.jaci.2014.04.001
Pubmed
24797422
Web of science
000338930300036
Création de la notice
20/01/2015 18:48
Dernière modification de la notice
20/08/2019 14:28
Données d'usage